Precision medicine has long promised to match the right treatment to the right patient. CAR-T cell therapy, gene editing, and advanced cell therapies take that promise considerably further—not by targeting symptoms more accurately, but by intervening at the molecular level where disease originates. A patient’s own T cells can be reprogrammed to recognise and destroy cancer. Defective genes can be replaced, repaired, or silenced. Tissue function and immune balance can be restored through engineered cellular interventions that would have seemed implausible to clinicians a generation ago.
The global cell and gene therapy market, valued at approximately $27 to $36.5 billion in 2025, is projected to reach between $183 and $232 billion by the mid-2030s—a trajectory that reflects not speculative enthusiasm but a genuine and accelerating shift in the clinical pipeline, with more regulatory approvals, more trials, and a rapidly expanding range of indications moving well beyond oncology.
CAR-T Therapy: From Haematological Breakthrough to Broader Clinical Frontier
CAR-T cell therapy has become the most clinically visible and commercially compelling success story in the advanced therapeutics field. The mechanism is elegantly patient-specific: T cells are collected from the individual, genetically reprogrammed to express chimeric antigen receptors that recognise a defined tumour target, expanded in controlled manufacturing conditions, and reinfused to mount a directed immune assault. In haematological malignancies—leukaemia, lymphoma, and multiple myeloma—this approach has produced clinical responses in patients who had exhausted conventional treatment options, establishing CAR-T as a genuine therapeutic rather than an experimental last resort.
The scale of global activity reflects this clinical validation. A 2025 review identified 1,744 CAR clinical trials registered on ClinicalTrials.gov as of 2024, with approximately 92 per cent targeting tumour indications and 65 per cent concentrated in haematologic malignancies. CD19 and BCMA remain the dominant targets in late-stage development, whilst dual, bispecific, and universal CAR constructs are advancing as researchers address antigen escape and tumour heterogeneity—the biological mechanisms through which cancers have historically evaded single-target approaches.
The field’s expansion into solid tumours represents both its most significant remaining challenge and its most consequential research frontier. Work presented at ASCO 2025 highlights ongoing progress in mesothelin-targeted approaches and other solid-tumour programmes, and whilst biological obstacles remain substantial, the trajectory of research investment signals that solid-tumour CAR-T is a question of scientific timing rather than fundamental feasibility.
Gene Therapy: Fixing the Molecular Cause Rather Than Managing Its Consequences
Gene therapy operates on a different but complementary principle: rather than mobilising the immune system against disease, it intervenes at the genetic level to correct, replace, or silence the molecular instruction responsible for pathology. This has made it particularly powerful in rare genetic disorders, haemophilia, inherited retinal disease, and metabolic conditions where a single gene defect drives severe and progressive clinical outcomes. The approval of Casgevy—the first CRISPR-based therapeutic cleared in the United States—marked a definitional moment for the field, demonstrating that gene editing could complete the journey from laboratory concept to regulated clinical medicine and establishing a regulatory precedent that has subsequently accelerated review processes for comparable programmes.
ASGCT’s 2025 quarterly landscape report documented multiple additional approvals across gene, cell, and RNA modalities, including an AAV gene therapy for haemophilia B in Canada and continued global pipeline activity that signals sustained institutional confidence in the technology’s clinical and commercial viability.
Perhaps the most strategically significant finding in recent pipeline data is the diversification of indications: 51 per cent of newly initiated gene therapy trials are now for non-oncology conditions, up from 39 per cent year-over-year. This shift indicates that gene therapy is evolving from a highly specialised intervention for rare and life-threatening conditions into a broader clinical tool capable of serving substantially larger patient populations—a transition critical to the long-term commercial sustainability and health system integration of the modality.
Manufacturing, Access, and the Infrastructure That Will Define the Next Decade
The scientific progress in advanced therapies is extraordinary by any historical standard. The barriers to realising its full clinical and social potential are equally formidable. Personalised cell therapies require patient-specific collection, engineering, quality testing, and reinfusion—a manufacturing process that is fundamentally difficult to standardise, expensive to operate, and logistically demanding to deliver through conventional healthcare supply chains. Manufacturing remains the single largest bottleneck constraining the field’s expansion from elite academic medical centres into broader health systems.
The industry’s response is concentrated in three parallel approaches: allogeneic off-the-shelf cell therapy platforms that eliminate patient-specific manufacturing requirements; automated personalised manufacturing systems that reduce per-unit production costs whilst maintaining quality; and localised manufacturing hubs that bring production closer to patient populations in regions where centralised supply chains impose prohibitive costs and access inequities. Each of these approaches carries distinct scientific, regulatory, and commercial challenges, but together they represent the manufacturing innovation agenda upon which advanced therapies’ transition from breakthrough to standard-of-care genuinely depends.
Access and reimbursement present an equally urgent structural challenge. Market growth projections through the mid-2030s demonstrate investor confidence, but they simultaneously underline the risk that precision medicine becomes precisely that—medicine available with precision only to those who can access and afford it.
Smarter reimbursement models, outcomes-based payment frameworks, and regional manufacturing strategies are not peripheral considerations for health systems evaluating advanced therapies; they are the prerequisites for ensuring that scientific achievement translates into population-level health impact. The next generation of precision medicine will be defined by whether its extraordinary therapeutic potential can be matched by institutional creativity equal to the challenge of delivering it equitably at scale.